Skip to main content
Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
2.300
-0.090 (-3.77%)
At close: Nov 13, 2026, 4:00 PM EST
2.280
-0.020 (-0.87%)
After-hours: Nov 13, 2026, 7:30 PM EST

Rocket Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
68.9686.5101.9670.3258.7741.77
Research & Development
121.47142.02171.24186.34165.07124.48
Operating Expenses
190.43228.52273.21256.66223.84166.25
Operating Income
-190.43-228.52-273.21-256.66-223.84-166.25
Interest Expense
-1.89-1.89-1.89-1.88-1.86-2.98
Interest & Investment Income
2.213.228.275.293.893.07
EBT Excluding Unusual Items
-190.11-227.19-266.82-253.25-221.82-166.16
Merger & Restructuring Charges
0.07-3.23--3--
Gain (Loss) on Sale of Investments
4.377.38.0810.65-0.05-2.91
Pretax Income
-7.48-223.12-258.75-245.6-221.86-169.07
Net Income
-16.15-223.12-258.75-245.6-221.86-169.07
Net Income to Common
-16.15-223.12-258.75-245.6-221.86-169.07
Net Income Growth
------
Shares Outstanding (Basic)
11311195846863
Shares Outstanding (Diluted)
11311195846863
Shares Change
4.69%17.21%12.85%23.27%7.77%14.18%
EPS (Basic)
-0.14-2.01-2.73-2.92-3.26-2.67
EPS (Diluted)
-0.14-2.01-2.73-2.92-3.26-2.67
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-159.23-190.45-215.59-211.35-186.5-128.78
Free Cash Flow Per Share
-1.41-1.71-2.27-2.52-2.74-2.04
EBITDA
-181.93-217.49-263.83-249.56-217.58-160.88
D&A For EBITDA
8.511.039.387.16.275.37
EBIT
-190.43-228.52-273.21-256.66-223.84-166.25
SEC Filings: 10-K · 10-Q